On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Researchers describe the molecular mechanisms by which the GBA gene, the main genetic risk factor, associates with the accumulation of α-synuclein in neurons.

It is the project “New Nanotechnological Therapy for Parkinson’s disease: Nose to Brain Delivery of GBA-Polymer Nanoconjugates (nanoGBAtoBrain)”.

La primera jornada dedicada a aquesta malaltia organitzada pel Campus Vall d’Hebron ha reunit més de 150 assistents.

As of tomorrow, Lleida will be hosting the 19th Congress of the Spanish Society of Neuroscience (SENC). This is a biennial event, which this year will be held from 3 to 5 November in la Llotja, the Lleida Exhibition Centre.

The Aligning Science Across Parkinson's (ASAP) initiative has awarded the grant to a project coordinated by Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at the Vall d'Hebron Research Institute (VHIR).

Deu investigadors i investigadores de Vall d’Hebron presenten xerrades i tallers en una jornada de divulgació científica per donar a conèixer la recerca i la innovació.